Vaxcyte (PCVX) Other Accumulated Expenses (2019 - 2023)

Vaxcyte (PCVX) has 5 years of Other Accumulated Expenses data on file, last reported at $1.9 million in Q4 2023.

• Other Accumulated Expenses for Q4 2023 came in at $1.9 million, up 34.66% year-over-year; the trailing twelve-month figure through Dec 2023 was $1.9 million (up 34.66% YoY), and the FY2023 annual result was $1.9 million, up 34.66% from the prior year.
• Other Accumulated Expenses slipped to $1.9 million in Q4 2023 per PCVX's latest filing, from $2.5 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $5.0 million in Q3 2021 and troughed at $64000.0 in Q4 2019.
• A 5-year average of $1.8 million and a median of $1.5 million in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2021 and 2022: Other Accumulated Expenses jumped 1267.24% in 2021, then sank 76.67% in 2022.
• A 5-year view of Other Accumulated Expenses shows it stood at $64000.0 in 2019, then soared by 575.0% to $432000.0 in 2020, then soared by 746.76% to $3.7 million in 2021, then plunged by 61.43% to $1.4 million in 2022, then soared by 34.66% to $1.9 million in 2023.
• Business Quant data shows PCVX's Other Accumulated Expenses at $1.9 million in Q4 2023, $2.5 million in Q3 2023, and $1.9 million in Q2 2023.